(Q38135689)

29 August 2017

Pegylated liposomal doxorubicin: a guide to its use in various malignancies (English)

1 reference

Katherine A Lyseng-Williamson

29 August 2017

1 reference

series ordinal

1

object named as

Katherine A Lyseng-Williamson

1 reference

29 August 2017

3

Gillian M Keating

1 reference

29 August 2017

Sean T Duggan

2

1 reference

29 August 2017

1 October 2013

1 reference

29 August 2017

1 reference

29 August 2017

27

1 reference

29 August 2017

5

1 reference

29 August 2017

533-540

1 reference

https://scigraph.springernature.com/pub.10.1007/s40259-013-0070-1

29 August 2017

0 references

cites work

Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0070-1

Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0070-1

Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0070-1

Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0070-1

Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0070-1

Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0070-1

Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0070-1

Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0070-1

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0070-1

Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0070-1

High cumulative doses of pegylated liposomal doxorubicin are not associated with cardiac toxicity in patients with gynecologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0070-1

Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0070-1

Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0070-1

Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0070-1

Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer: results of a multicenter phase-II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0070-1

10.1007/S40259-013-0070-1

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference

PubMed ID

24018470